Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a slow-digesting starch diet help tame type 2 diabetes?

NCT ID NCT03847701

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a diet rich in slowly digestible starch (SDS) could improve blood sugar control and reduce inflammation in people with type 2 diabetes. Fifty-three adults with type 2 diabetes followed either a high-SDS or low-SDS diet for three months. Researchers measured blood sugar patterns and other health markers to see if the high-SDS diet offered benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diet high in slowly digestible starch
What this could lead to
If it works, this could point toward a dietary approach to help manage blood sugar and reduce inflammation in type 2 diabetes.
What could go wrong
This is a small, completed dietary study with 53 participants, so results may not apply broadly. Dietary changes can be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

53 people

The number who actually took part.

Started

Jun 2019

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient able to understand the study information and providing written consent for his/her participation to the study * Male or female * Patient undergoing medical examination during the selection visit * Patient aged between 18 and 75 years old (bounds included) * T2D volunteer with HbA1c between 7% and 8,5% without signs of insulinopenia according to the investigator * Patient with BMI ranging between 25 and 40 kg/m2 (bounds included) * Patient with stable body weight over the past three months (+/- 5 % of body weight) * Patient accepting to change its diet for three months * Patient not suffering from food intolerance or allergy * Patient regularly consuming products proposed in the study * Patient agreeing to consume 3 main meals per day without extra-prandial carbohydrates intakes * Sedentary behavior or stable predicted physical activity during the study * Patient not presenting any disease during the medical examination / interview which could interfere with the results of the study according to the investigator * Patient covered by health insurance * Patient accepting to have short nails on his/her 2 forefingers Exclusion Criteria: * Patient under legal protection measure * Patient deprived of liberty by a court or an administrative decision * Patient currently participating in another study or being in the exclusion period of another study * Volunteer that exceed the financial compensation allowed per year for participating in research programs * Gamma-GT \> 2.5 times above the norm (\>160 UI/L) * ASAT \> 2.5 times above the norm (\>85 UI/L) * ALAT \> 2.5 times above the norm (\>137.5 UI/L) * Triglycerides \> 4 g/L * LDL-cholesterol \> 1.90 g/L * CRP \> 15 mg/L * Hemoglobin \< 120 mg/dL * eGRF (estimated glomerular filtration rate) \< 45 ml/min * Other biological abnormality with clinical significant relevance according to the investigator * Patient with type 1 diabetes, post pancreatectomy or post transplant diabetes, MODY diabetes, mitochondrial diabetes, iatrogenic diabetes * T2D volunteer with any other anti-diabetic treatment other than metformin: insulin therapy, GLP-1 analogues, acarbose, sulphonylureas, repaglinide, SGLT2 agonists,… * Patient consuming in the two previous months regularly corticoids, beta-blocking drugs or immunosuppressing drugs * Patient with hemoglobin pathology * Patient with medical history of hemoglobinopathies (thalassemia, drepanocytosis…) * Patient with past bariatric surgery * Patient with medical history of endocrine diseases who may interfere with glucose metabolism according to the investigator (such as hyperthyroidism, acromegaly, hypercorticism…) * Patient treated with anticoagulants * Patient with a pace-maker * Uncontrolled high blood pressure defined by Systolic blood pressure \> 150 mmHg or Diastolic blood pressure \> 100 mmHg * Evidence of any other unstable or untreated clinically significant immunological, neoplasic, endocrine, haematological, gastrointestinal, hepatic, neurological or psychiatric abnormalities or medical disease with clinical significant relevance according to the investigator * Pregnant women or willing to become pregnant or lactating women * Women of childbearing age without an efficient contraceptive method according to the investigator * Patient under a restrictive diet or with a planned weight loss program during the study * Patient with severe eating disorders (e.g. anorexia nervosa, binge eating disorder and bulimia) according to the investigator * Patient without stable dietary habits or with specific diet (vegetarian, vegan, gluten-free…) according to the investigator * Patient who smokes more than 5 cigarettes per day * Patient regularly consuming more than 20 g/day of alcohol. Consumption of more than 3 alcoholic beverages per day is recognized as excessive. An alcoholic beverage is: 30 mL of spirituous, 120 mL of wine or 330 mL of beer * Patient regularly consuming recreational drugs * Adhesive plaster skin allergy * Claustrophobic patient * Patient willing to take the plane during the CGMS periods

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre de Recherche en Nutrition Humaine Rhone-Alpes

    Pierre-Bénite, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.